ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "AtriCure, Inc." (ATRC) Report Updated: May 23, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"AtriCure, Inc." (ATRC)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Health Care Equipment & Supplies
Competitors: PDEX,CMN,UTMD,MASI

Stock Analysis

Rating: Monthly View

A
B
C
D
F
May June July August September October November December January February March April

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"AtriCure, Inc."© quotemedia

Company Profile

AtriCure, Inc., a medical device company, provides atrial fibrillation solutions worldwide. The company offers Isolator Synergy ablation system and related radio frequency(RF) ablation devices, which include clamps that are used for ablation during open-heart procedures; ablation and sensing unit, a compact power generator that delivers bipolar RF energy to its clamps, multifunctional pens, and Coolrail linear ablation devices; AtriCure Switch Box, a compact switch box, which offers the technology needed for the dual pulsing electrodes in clamps; and Coolrail linear ablation device, a disposable linear RF ablation device that allows physicians to create an expanded cardiac ablation lesion set during minimally invasive procedures. It also provides Isolator multifunctional pens that enable surgeons to evaluate cardiac arrhythmias; perform temporary cardiac pacing, sensing, and stimulation; and ablate cardiac tissue with the same device. In addition, the company provides Fusion surgical ablation system; Estech electrosurgical unit, a compact power generator for use with Fusion ablation products; AFfirm bipolar pacing probes used to test lesions created in surgically treating the patientís arrhythmia; cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; and AtriClip system that is designed for the left atrial appendage management. Further, it sells enabling technologies, including Lumitip dissector to separate tissues to provide access to anatomical structures that are targeted for ablation; and Estech cardiac surgery instruments that are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products to hospitals and medical centers through independent distributors and direct sales personnel. AtriCure, Inc. was founded in 2000 and is headquartered in West Chester, Ohio.